SCHEDULE 13G: RTW Investments and Dr. Roderick Wong Disclose 8.9% Stake in Rapt Therapeutics

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 8.9% in Rapt Therapeutics, Inc., holding 11,764,000 shares of common stock.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in Rapt Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 11,764,000 shares of Rapt Therapeutics, Inc. Common Stock.
• This ownership represents 8.9% of the outstanding Common Stock of Rapt Therapeutics, Inc.
• The percentage is calculated based on 132,006,828 shares outstanding as of April 4, 2025, as reported in the Company's Definitive Proxy Statement filed on April 14, 2025.
• Both RTW Investments, LP and Roderick Wong, M.D. hold shared voting power and shared dispositive power over all 11,764,000 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is a routine regulatory filing and does not inherently convey positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an institutional investor in a publicly traded company, common within the investment and biotechnology sectors.

Stakeholder Impact

• Shareholders are informed of a significant institutional stake in the company, providing transparency regarding the ownership structure.

Key Dates

Keywords

Rapt Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology